Eledon Pharmaceuticals
ELDN
95 hedge funds and large institutions have $66.7M invested in Eledon Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 19 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 17
76% more call options, than puts
Call options by funds: $153K | Put options by funds: $87K
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
14% more funds holding
Funds holding: 83 → 95 (+12)
12.77% more ownership
Funds ownership: 60.9% → 73.67% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $94.5M → $66.7M (-$27.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$4.33M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$3.76M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$2.85M |
| 4 |
AIC
AWM Investment Company
New York
|
+$2.61M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.24M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$5.37M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.33M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.96M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.07M |
ELDN Hedge Fund Activity: Q4 2025 in Review
95 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2025, worth a combined $66.7M — down 29% from $94.5M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ELDN positions and 19 closed out — a net gain of 13 holders — while 32 added to existing stakes and 17 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $4.33M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.24M sold.
- 95 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2025, up from 83 in Q3 2025.
- Funds reported $66.7M of Eledon Pharmaceuticals stock for Q4 2025, down 29% quarter-over-quarter.
- 32 funds opened new Eledon Pharmaceuticals positions in Q4 2025 and 19 closed out, a net change of +13 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2025 was ADAR1 Capital Management, an estimated $4.33M added.
- The largest Eledon Pharmaceuticals seller in Q4 2025 was RA Capital Management, an estimated $9.24M sold.
Based on aggregated 13F filings for Q4 2025.